SB1983 declares that any convention, agreement, or other international instrument on pandemic prevention, preparedness, and response produced by the World Health Assembly pursuant to the International Negotiating Body (INB) is legally ‘‘deemed’’ a treaty and therefore subject to Article II, Section 2 of the Constitution — the Senate’s advice and consent requirement with a two‑thirds vote. The bill includes an express override—"notwithstanding any other provision of law"—to block the executive branch from treating such instruments as non‑treaty executive agreements.
This changes how the United States would approach WHO outputs from the INB by converting what might otherwise be negotiated as a binding executive agreement into an item that requires formal Senate ratification or implementing legislation. For negotiators, agencies, and foreign partners, the bill replaces flexibility with an institutional check that could delay or prevent U.S. acceptance and implementation of multilateral pandemic rules and mechanisms.
At a Glance
What It Does
The bill automatically treats any WHA instrument on pandemic prevention, preparedness, and response arising from the INB as a treaty requiring Senate advice and consent under Article II. It does this by statute and includes language overriding contrary legal authorities and past practice.
Who It Affects
The executive branch—principally the State Department, HHS, and other agencies that negotiate with WHO—will face a new statutory requirement. The U.S. Senate gains a clear gatekeeping role; international partners and WHO negotiators will encounter a procedural constraint when expecting U.S. commitments.
Why It Matters
It shifts the decision from executive discretion to formal Senate ratification, which could materially slow down U.S. participation in WHO pandemic accords and reshape negotiating leverage. Compliance officers, treaty counsel, and international health negotiators need to plan for potential legislative steps before U.S. implementation.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
SB1983 takes a single, narrow legal approach: whatever text emerges from the World Health Assembly as a product of the INB’s work on pandemic prevention, preparedness, and response is to be treated by U.S. law as a treaty. By statute, the bill removes any ambiguity about whether such instruments can be adopted or implemented by the President alone as executive agreements.
That statutory command is framed broadly — it applies to conventions, agreements, or “other international instruments” tied to the INB’s final report.
The bill also memorializes a set of factual findings and a ‘‘sense of the Senate’’ that explain the drafters’ rationale: a loss of public trust in WHO, the breadth of topics the INB has considered, and the Department of State’s own criteria (FAM 723.3) for deciding treaty versus executive agreement status. While those findings are nonbinding, they signal that the Senate intends to assert control over any multilateral pandemic framework produced through the INB.Practically, the statutory deeming has two immediate effects.
First, U.S. negotiators lose a ready path to bind the United States quickly via executive agreement on items that the bill covers. Second, unless the Senate provides advice and consent or Congress enacts implementing legislation, the United States would be unable to lawfully commit to—and probably would decline to implement—binding obligations contained in such a WHA instrument.
That creates a predictable but potentially slow route from negotiation to domestic effect: negotiation at WHO → submission and Senate consideration → possible treaty ratification or enabling statutes.
The Five Things You Need to Know
Section 4 declares that any WHA convention, agreement, or other international instrument on pandemic prevention, preparedness, and response arising from the INB is "deemed to be a treaty" subject to Article II, Section 2 of the U.S. Constitution.
The bill contains an explicit override—"notwithstanding any other provision of law"—preventing the Executive from treating covered WHO instruments as non‑treaty executive agreements.
The statutory scope is limited to instruments "reached by the World Health Assembly pursuant to the recommendations, report, or work of the International Negotiating Body" established at the WHA special session.
The bill’s findings cite the Department of State Foreign Affairs Manual (section 723.3) criteria for deciding treaty status and uses those criteria to argue the INB product should be a treaty.
A separate 'sense of the Senate' provision states that the United States should not agree to or implement any relevant WHA agreement that cannot secure two‑thirds Senate approval, signaling congressional intent even though that language is nonbinding.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Designates the act’s name as the "No WHO Pandemic Preparedness Treaty Without Senate Approval Act." This is a framing device: the title signals intent to domestic and international audiences that the statute aims to block executive-only acceptance of certain WHO instruments.
Findings
Lists historical events, public opinion data, INB topics, and the State Department FAM criteria to justify congressional concern. These findings do not create legal obligations, but they establish the factual and policy predicate the sponsors rely on to argue that INB outputs implicate national sovereignty and therefore warrant Senate involvement.
Sense of the Senate
Expresses Senate preferences: that covered WHA agreements should be treated as treaties requiring two‑thirds approval and that the United States should not implement such agreements without that approval. Although nonbinding, this section is a political signal that could influence executive conduct and provide floor managers with a public rationale when opposing executive negotiation outcomes.
Deeming clause: INB outputs are treaties
Imposes the operative legal rule. By statutory fiat, instruments on pandemic prevention, preparedness, and response developed by the INB and adopted by the WHA are "deemed to be a treaty" subject to Article II advice and consent. The provision’s "notwithstanding any other provision of law" phrasing aims to invalidate executive‑branch practices that treat similar international instruments as executive agreements and obliges the executive to seek Senate approval or rely on implementing legislation before accepting binding obligations.
This bill is one of many.
Codify tracks hundreds of bills on Foreign Affairs across all five countries.
Explore Foreign Affairs in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- U.S. Senate and treaty proponents — Gains institutional control over pandemic‑related international commitments by requiring formal advice and consent before binding the nation.
- Domestic interest groups skeptical of WHO authority — Receive a statutory barrier that makes it harder for international pandemic rules to be imposed on U.S. entities without congressional input.
- Congressional oversight staff and treaty counsel — Obtain clearer legal footing and a predictable process for reviewing any INB‑derived instrument, enabling structured oversight and legislative responses.
- Industries wary of new international regulatory obligations (e.g., pharmaceutical manufacturers, data controllers) — Benefit from reduced risk of rapid, binding international mandates that could affect domestic regulation without legislative review.
Who Bears the Cost
- Executive branch negotiators (State, HHS, others) — Lose flexibility to conclude binding international agreements quickly; will need to factor in likely Senate involvement when bargaining and may have less leverage or speed in negotiations.
- International partners and WHO — Face greater uncertainty about U.S. commitments and a higher political hurdle to secure U.S. ratification, which could complicate consensus on global pandemic measures.
- Public health emergency response capability — Risks slower integration of multilateral coordination tools or standards into U.S. law, potentially delaying interoperable responses or shared access mechanisms during crises.
- Federal agencies tasked with implementation (CDC, NIH, FDA) — Could incur new administrative and legislative burdens if implementing legislation is required to give effect to obligations, increasing costs and timelines.
Key Issues
The Core Tension
The central dilemma is between constitutional accountability and operational agility: SB1983 strengthens democratic oversight by insisting on Senate ratification for INB‑derived WHO instruments, but in doing so it may undermine the executive branch’s ability to secure quick international cooperation and operational commitments needed during fast‑moving global health emergencies.
The bill resolves a constitutional‑style question—treaty versus executive agreement—by statute rather than by adjudication or executive practice. That statutory resolution invites disputes about its scope and enforceability.
The text hinges on the phrase "reached by the World Health Assembly pursuant to the recommendations, report, or work of the INB," which can be read narrowly (only final INB products) or broadly (including related WHO instruments). That ambiguity creates litigation risk and uncertain diplomatic signals during ongoing negotiations.
Operationally, treating INB outputs as automatically subject to Senate ratification trades speed for democratic oversight. In a fast‑moving pandemic, the United States might be unable to accept time‑sensitive obligations or partake in allocation mechanisms without first securing Senate approval or separate implementing statutes—processes that can take months.
The bill’s "notwithstanding any other provision of law" language also raises separation‑of‑powers questions: it constrains the President’s usual foreign‑affairs tools and could provoke constitutional challenge or reciprocal measures by other states, complicating multilateral cooperation.
Finally, the bill relies partly on political tools—findings and a nonbinding sense of the Senate—to shape behavior. Those signals can impede executive negotiation even if the statutory deeming is narrow.
The practical outcome will depend on how strictly agencies and negotiators read the statute, how courts treat its claims if litigated, and whether the Senate chooses to act on any instrument it receives.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.